Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 32, 2008, Pages 11105-11109

  Chen, Qi ^a   Espey, Michael Graham ^a   Sun, Andrew Y ^a   Pooput, Chaya ^a   Kirk, Kenneth L ^a   Krishna, Murali C ^b   Khosh, Deena Beneda ^c   Drisko, Jeanne ^c   Levine, Mark ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

Cancer; Free radical; Hydrogen peroxide; Oxidation; Vitamin C

Indexed keywords

ASCORBIC ACID; HYDROGEN PEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL VIABILITY; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG METABOLISM; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ASCORBIC ACID; FEMALE; HUMANS; HYDROGEN PEROXIDE; INFUSIONS, INTRAVENOUS; MICE; MICE, NUDE; NEOPLASMS; OXIDANTS; PRODRUGS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 49649115940     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804226105     Document Type: Article

References (25)

1. Padayatty SJ, et al. (2003) Vitamin C as an antioxidant: Evaluation of its role in disease prevention. J Am Coll Nutr 22:18-35.
2. Zhang S, et al. (1999) Dietary carotenoids and vitamins A, C, and E and risk of breast cancer J Natl Cancer Inst 91:547-556.
3. Hung HC, et al. (2004) Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst 96:577-584.
4. Chen Q, et al. (2005) Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102:13604-13609.
5. Chen Q, et al. (2007) Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 104:8749-8754.
6. Levine M, et al. (1996) Vitamin C pharmacokinetics in healthy volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 93:3704-3709.
7. Levine M, Wang Y, Padayatty SJ, Morrow J (2001) A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci USA 98:9842-9846.
8. Padayatty SJ, et al. (2004) Vitamin C pharmacokinetics: Implications for oral and intravenous use. Ann Intern Med 140:533-537.
9. Menon M, Maramag C, Malhotra RK, Seethalakshmi L (1998) Effect of vitamin C on androgen independent prostate cancer cells (PC3 and Mat-Ly-Lu) in vitro: Involvement of reactive oxygen species-effect on cell number, viability and DNA synthesis. Cancer Biochem Biophys 16:17-30.
10. Cameron E, Pauling L (1976) Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73:3685-3689.
11. Cameron E, Pauling L (1978) Supplemental ascorbate in the supportive treatment of cancer: Reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 75:4538-4542.
12. Creagan ET, et al. (1979) Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301:687-690.
13. Moertel CG, et al. (1985) High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312:137-141.
14. Wittes RE (1985) Vitamin C and cancer. N Engl J Med 312:178-179.
15. Padayatty SJ, Levine M (2000) Reevaluation of ascorbate in cancer treatment: Emerging evidence, open minds and serendipity. J Am Coll Nutr 19:423-425.
16. Hoffer LJ, et al. (2008) Phase I clinical trial of intravenous ascorbate in advanced malignancy. Annal Oncol, in press.
17. Padayatty SJ, et al. (2006) Intravenously administered vitamin C as cancer therapy: Three cases. Can Med Assoc J 174:937-942.
18. Stone JR, Yang S (2006) Hydrogen peroxide: A signaling messenger. Antioxid Redox Signal 8:243-270.
19. Englard S, Seifter S (1986) The biochemical functions of ascorbic acid. Annu Rev Nutr 6:365-406.
20. Bruegge K, Jelkmann W, Metzen E (2007) Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem 14:1853-1862.
21. Tsantes AE, Bonovas S, Travlou A, Sitaras NM (2006) Redox imbalance, macrocytosis, and RBC homeostasis. Antioxid Redox Signal 8:1205-1216.
22. Roy S, Khanna S, Nallu K, Hunt TK, Sen CK (2006) Dermal wound healing is subject to redox control. Mol Ther 13:211-220.
23. Arbiser JL, et al. (2002) Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 99:715-720.
24. Teoh ML, Sun W, Smith BJ, Oberley LW, Cullen JJ (2007) Modulation of reactive oxygen species in pancreatic cancer. Clin Cancer Res 13:7441-7450.
25. Ahmed SA, Gogal RM Jr., Walsh JE (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H]thymidine incorporation assay. J Immunol Methods 170:211-224.